drugset
drugset / Trial / NCT00056797

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

NCT00056797 ↗

Phase 2 Completed 92 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedFactorialSingle-blindTreatment

Summary

This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in people with HIV infection.

Timeline

Start
2002-03
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ALVAC vCP1452 Vaccine — Intramuscular
Subject aldesleukin Protein / enzyme biologic 2e+06 iu Subcutaneous

Indications

HIV infectious disease